CHARLOTTE, N.C.--(BUSINESS WIRE)--Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience are announcing a landmark collaboration to accelerate global clinical trials and research innovation, improve patient outcomes and reduce health disparities.

北卡罗来纳州夏洛特——（商业新闻短讯）——Premier，Inc.的PINC AI™应用科学（PAS）和TFS HealthScience宣布了一项里程碑式的合作，以加速全球临床试验和研究创新，改善患者预后并减少健康差异。

The partnership will combine TFS’ capabilities, systems and clinical development expertise with PAS’ AI-enabled technology and comprehensive healthcare database. The collaboration will help expedite site and patient enrollment, reduce trial costs, accelerate the journey to commercialization, and ensure equitable access to groundbreaking medical solutions across diverse patient populations..

该合作关系将TFS的能力、系统和临床开发专业知识与PAS的人工智能技术和全面的医疗保健数据库相结合。该合作将有助于加快网站和患者注册，降低试验成本，加速商业化进程，并确保不同患者群体公平获得开创性的医疗解决方案。。

Eighty percent of all trials face premature termination or significant delays due to recruitment challenges – and marginalized populations, including Black and Hispanic individuals, remain historically underrepresented.

由于招聘挑战，80%的试验面临提前终止或重大延误，包括黑人和西班牙裔在内的边缘化人群在历史上仍然代表性不足。

Leveraging comprehensive real-world data (RWD) and AI-enabled tools from PAS, TFS will gain enhanced capabilities to assess site suitability on a larger scale and focus on appropriate patient populations, investigator availability, therapeutic areas expertise and historical clinical trial performance metrics.

TFS将利用PAS提供的全面的真实世界数据（RWD）和AI支持的工具，增强更大规模评估站点适用性的能力，并专注于适当的患者人群，研究人员可用性，治疗领域专业知识和历史临床试验表现指标。

This data-driven approach has already enabled PAS-supported trials to improve recruitment by 1800 percent and triple enrollment compared to baseline projections – significantly reducing enrollment periods and costs..

这种数据驱动的方法已经使PAS支持的试验比基线预测提高了1800%的招募率和三倍的注册率，从而大大缩短了注册时间和成本。。

“The PAS-TFS partnership will bring the advantages of high-quality RWD/RWE and the benefits of AI-enabled technology to trial sponsors, investigators and life sciences entities worldwide,” said Denise Juliano, Group Vice President of Life Sciences at Premier. “Our combined strengths will help enhance data analysis, provide trial designs that are both diverse and equitable, advance early disease detection and reduce disparities with aim to advance global health equity.”.

Premier生命科学集团副总裁丹尼斯·朱利安诺（DeniseJuliano）表示：“PAS-TFS合作伙伴关系将为全球的试验赞助商、研究人员和生命科学实体带来高质量RWD/RWE的优势和人工智能技术的好处。”。“我们的综合优势将有助于加强数据分析，提供多样化和公平的试验设计，促进早期疾病检测并减少差异，以促进全球健康公平。”。

Dr. Bassem Saleh, Chief Executive Officer at TFS, emphasizes the global impact of the collaboration: “Technology, including AI, will help accelerate clinical research through efficient clinical trial designs, synthetic arms and faster patient identification and recruitment. Working with PAS will open new avenues for innovative clinical trials in Europe and the U.S., benefiting biotech, pharma and medical device companies across various phases and RWE studies and ensuring more inclusive and patient-centric research.”.

TFS首席执行官巴塞姆·萨利赫博士，强调合作的全球影响：“包括人工智能在内的技术将通过有效的临床试验设计、合成武器以及更快的患者识别和招募来帮助加速临床研究。与PAS合作将为欧洲和美国的创新临床试验开辟新途径，使生物技术、制药和医疗器械公司在各个阶段和RWE研究中受益，并确保更具包容性和pat以客户为中心的研究。”。

The PAS-TFS partnership has plans for implementation in multiple studies per year across all therapeutic areas and indications. Data-driven designs will enable sponsors to integrate decentralized approaches with an emphasis on remote health and in-home patient monitoring options using mobile apps and wearables, helping lower overall trial costs..

PAS-TFS合作伙伴计划每年在所有治疗领域和适应症中进行多项研究。数据驱动的设计将使赞助商能够整合分散的方法，重点是使用移动应用程序和可穿戴设备的远程健康和家庭患者监测选项，从而有助于降低总体试验成本。。

This strategic collaboration is set to further enable TFS’s expansion in the U.S. and enhance PINC AI’s global influence, especially in the European market, leveraging TFS’s extensive network. By uniting their capabilities, PAS and TFS are committed to driving forward innovation in clinical research and offering efficient solutions that prioritize patient health outcomes and equity..

这一战略合作旨在利用TFS的广泛网络，进一步推动TFS在美国的扩张，增强PINC AI的全球影响力，尤其是在欧洲市场。通过联合他们的能力，PAS和TFS致力于推动临床研究创新，并提供有效的解决方案，优先考虑患者的健康结果和公平。。

About TFS HealthScience

关于TFS HealthScience

TFS HealthScience is a global clinical Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through two strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process and Strategic Resourcing Solutions (SRS), which offers expert insourcing, targeted recruitment, and strategic workforce management solutions..

TFS HealthScience是一家全球临床合同研究组织（CRO），在整个临床开发过程中为生物技术和制药公司提供支持。与客户合作，我们建立解决方案驱动的团队，为更健康的未来而努力。TFS汇集了近800名专业人员，在40多个国家/地区提供量身定制的临床研究服务，并通过两种强大的商业模式为客户提供全面的解决方案：临床开发服务（CDS），它在临床开发过程的各个阶段提供全方位的服务支持和战略资源解决方案（SRS），它提供专家内包、有针对性的招聘和战略性劳动力管理解决方案。。

About PINC AI™ Applied Sciences (PAS)

关于PINC AI™应用科学（PAS）

PAS is a trusted leader in accelerating healthcare improvement through services, data and scalable solutions, spanning the continuum of care and enabling sustainable innovation and rigorous research. These services and RWD are valuable resources for the pharmaceutical, device and diagnostic industries, academia, federal and national healthcare agencies, as well as hospitals and health systems.

PAS在通过服务、数据和可扩展解决方案加速医疗保健改进、跨越连续护理、实现可持续创新和严格研究方面是值得信赖的领导者。这些服务和RWD是制药、设备和诊断行业、学术界、联邦和国家医疗机构以及医院和卫生系统的宝贵资源。

Since 2000, PAS researchers have produced more than 1,000 publications which appear in 264 scholarly, peer-reviewed journals, covering a wide variety of topics, and conduct population-based analyses of drugs, devices, treatments, disease states, epidemiology, resource utilization, healthcare economics and clinical outcomes..

自2000年以来，PAS研究人员已经发表了1000多篇出版物，出现在264种学术同行评审期刊上，涵盖了各种各样的主题，并对药物，设备，治疗，疾病状态，流行病学，资源利用，医疗保健经济学和临床结果进行了基于人群的分析。。

About the PINC AI™ Platform

关于PINC AI™平台

PINC AI™ is the technology and services platform of Premier, Inc. (NASDAQ: PINC). With more than 20 years’ worth of cost, quality and operational data gleaned from 45 percent of U.S. hospital discharges, 2.7 billion hospital outpatient and clinic encounters and 177 million physician office visits, the PINC AI™ platform provides actionable intelligence to help improve outcomes, support improved financial performance and enable success in new, alternative payment models.

PINC AI公司™是Premier，Inc.（纳斯达克代码：PINC）的技术和服务平台。PINC AI收集了美国45%的医院出院、27亿次医院门诊和诊所就诊以及1.77亿次医生办公室就诊的20多年的成本、质量和运营数据™该平台提供可操作的智能，以帮助改进结果，支持改进的财务绩效，并在新的替代支付模式中取得成功。

PINC AI™ incorporates the 100 Top Hospitals ® Program that inspires hospital and health system leaders to pursue higher performance and deliver added value to their patients and communities. PINC AI™ offerings rely on advanced analytics to identify improvement opportunities; support award-winning Strategic Collaboratives for value-based care, maternal and infant health, workforce innovation, and health equity; and consulting services for clinical and operational design, and workflow solutions to hardwire sustainable change.

PINC AI公司™纳入了100家顶级医院®计划，该计划激励医院和卫生系统领导者追求更高的绩效，并为患者和社区带来附加价值。PINC AI公司™产品依赖高级分析来确定改进机会；支持在基于价值的护理、母婴健康、劳动力创新和健康公平方面屡获殊荣的战略合作；临床和操作设计的咨询服务，以及硬线可持续变化的工作流程解决方案。

The PINC AI™ platform is also the data engine powering Premier’s newest brands – Remitra® and Contigo Health®. With a leading network of provider organizations, the PINC AI™ platform accelerates ingenuity and serves as a large-scale innovation catalyst in healthcare. PINC AI™ offerings and capabilities can be followed on X (formerly Twitter) and LinkedIn..

PINC AI™该平台也是为Premier最新品牌（Relimera®和Contigo Health®）提供动力的数据引擎。凭借领先的提供商组织网络，PINC AI™该平台加速了创造力，并成为医疗保健领域的大规模创新催化剂。PINC AI公司™可以在X（以前的Twitter）和LinkedIn上关注产品和功能。。